NCT01315795

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

An Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Lanreotide Autogel 90mg Every 4 Weeks in the Treatment of Symptomatic Polycystic Liver Disease, Including a Dose Escalation at Month 6 to Lanreotide Autogel 120mg for Non Responders

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 59 (actual)
• Sponsor: Universitaire Ziekenhuizen KU Leuven · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

An open-label, Phase II clinical study to evaluate the efficacy and safety of lanreotide autogel 90mg every 4 weeks in the treatment of symptomatic polycystic liver disease, including a dose escalation at month 6 to lanreotide autogel 120mg for non responders.

Conditions

• Polycystic Liver Disease

Interventions

Type	Name	Description
DRUG	Lanreotide Autogel 90 mg and 120 mg	administration of lanreotide sc every 4 weeks (28 days)

Timeline

• Start date: 2011-03-01
• Primary completion: 2014-07-01
• Completion: 2014-07-01
• First posted: 2011-03-15
• Last updated: 2014-07-08

Locations

1 site across 1 country: Belgium